Show simple item record

dc.contributor.authorRamcharan, Ren
dc.contributor.authorAleksic, Ten
dc.contributor.authorKamdoum, WPen
dc.contributor.authorGao, Sen
dc.contributor.authorPfister, SXen
dc.contributor.authorTanner, Jen
dc.contributor.authorBridges, Een
dc.contributor.authorAsher, Ren
dc.contributor.authorWatson, AJen
dc.contributor.authorMargison, GPen
dc.contributor.authorWoodcock, Men
dc.contributor.authorRepapi, Een
dc.contributor.authorLi, J-Len
dc.contributor.authorMiddleton, MRen
dc.contributor.authorMacaulay, VMen
dc.date.accessioned2017-11-29T12:31:57Z
dc.date.available2017-11-29T12:31:57Z
dc.date.issued2015-11-24en
dc.identifier.urihttp://hdl.handle.net/10026.1/10343
dc.description.abstract

Prior studies implicate type 1 IGF receptor (IGF-1R) in mediating chemo-resistance. Here, we investigated whether IGF-1R influences response to temozolomide (TMZ), which generates DNA adducts that are removed by O6-methylguanine-DNA methyltransferase (MGMT), or persist causing replication-associated double-strand breaks (DSBs). Initial assessment in 10 melanoma cell lines revealed that TMZ resistance correlated with MGMT expression (r = 0.79, p = 0.009), and in MGMT-proficient cell lines, with phospho-IGF-1R (r = 0.81, p = 0.038), suggesting that TMZ resistance associates with IGF-1R activation. Next, effects of IGF-1R inhibitors (IGF-1Ri) AZ3801 and linsitinib (OSI-906) were tested on TMZ-sensitivity, cell cycle progression and DSB induction. IGF-1Ri sensitized BRAF wild-type and mutant melanoma cells to TMZ in vitro, an effect that was independent of MGMT. Cells harboring wild-type p53 were more sensitive to IGF-1Ri, and showed schedule-dependent chemo-sensitization that was most effective when IGF-1Ri followed TMZ. This sequence sensitized to clinically-achievable TMZ concentrations and enhanced TMZ-induced apoptosis. Simultaneous or prior IGF-1Ri caused less effective chemo-sensitization, associated with increased G1 population and reduced accumulation of TMZ-induced DSBs. Clinically relevant sequential (TMZ → IGF-1Ri) treatment was tested in mice bearing A375M (V600E BRAF, wild-type p53) melanoma xenografts, achieving peak plasma/tumor IGF-1Ri levels comparable to clinical Cmax, and inducing extensive intratumoral apoptosis. TMZ or IGF-1Ri caused minor inhibition of tumor growth (gradient reduction 13%, 25% respectively), while combination treatment caused supra-additive growth delay (72%) that was significantly different from control (p < 0.01), TMZ (p < 0.01) and IGF-1Ri (p < 0.05) groups. These data highlight the importance of scheduling when combining IGF-1Ri and other targeted agents with drugs that induce replication-associated DNA damage.

en
dc.format.extent39877 - 39890en
dc.languageengen
dc.language.isoengen
dc.subjectIGF-1Ren
dc.subjectapoptosisen
dc.subjectchemo-sensitizationen
dc.subjectdouble strand breaken
dc.subjecttemozolomideen
dc.subjectAnimalsen
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen
dc.subjectApoptosisen
dc.subjectBlotting, Westernen
dc.subjectCell Line, Tumoren
dc.subjectCell Survivalen
dc.subjectDNA Breaks, Double-Strandeden
dc.subjectDacarbazineen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectDrug Synergismen
dc.subjectG1 Phase Cell Cycle Checkpointsen
dc.subjectHumansen
dc.subjectImidazolesen
dc.subjectMelanomaen
dc.subjectMice, Inbred BALB Cen
dc.subjectMice, Nudeen
dc.subjectMutationen
dc.subjectProto-Oncogene Proteins B-rafen
dc.subjectPyrazinesen
dc.subjectReceptor, IGF Type 1en
dc.subjectSurvival Analysisen
dc.subjectTemozolomideen
dc.subjectTumor Suppressor Protein p53en
dc.subjectXenograft Model Antitumor Assaysen
dc.titleIGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26497996en
plymouth.issue37en
plymouth.volume6en
plymouth.publication-statusPublisheden
plymouth.journalOncotargeten
dc.identifier.doi10.18632/oncotarget.5631en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeUnited Statesen
dcterms.dateAccepted2015-10-03en
dc.identifier.eissn1949-2553en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.18632/oncotarget.5631en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2015-11-24en
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV